PMID- 34047947
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220523
IS  - 2193-8210 (Print)
IS  - 2190-9172 (Electronic)
VI  - 11
IP  - 4
DP  - 2021 Aug
TI  - Psoriasis Severity Assessment Combining Physician and Patient Reported Outcomes: 
      The Optimal Psoriasis Assessment Tool.
PG  - 1249-1263
LID - 10.1007/s13555-021-00544-6 [doi]
AB  - INTRODUCTION: Psoriasis Area Severity Index (PASI) assessment is complex and 
      time-consuming. A simpler assessment measure more sensitive to changes in symptom 
      severity and predictive of patients' quality of life (Dermatology Life Quality 
      Index, DLQI) is needed. This study aims to evaluate the Optimal Psoriasis 
      Assessment Tool (OPAT) as an alternative to PASI. METHODS: This integrated 
      analysis of three UNCOVER trials (NCT01474512, NCT01597245, and NCT01646177) 
      randomized patients (N = 3866) with moderate-to-severe psoriasis to 
      subcutaneously administered ixekizumab 80 mg Q2W or Q4W, or placebo or etanercept 
      50 mg Q2W. Pearson correlations were computed for clinical and patient-reported 
      measures with PASI and DLQI. RESULTS: As the correlations with PASI and BSA were 
      high and not much higher when adding severity, body surface area (BSA) was used 
      for the clinical measure. BSA was the main measure influencing OPAT. Week 12 
      regression analyses results showed that PASI had a higher correlation with BSA 
      combined with patient assessments than with BSA alone. Sensitivity analyses were 
      also completed for PASI 75 and 90. For DLQI, correlations with the combined 
      measures were even stronger than with BSA alone. A comprehensive model selection 
      procedure was conducted, which illustrated that the two-term models are 
      preferred. CONCLUSION: The OPAT is a simple and time-saving alternative to PASI. 
      It can be derived using BSA and patient-reported assessments having strong 
      correlation with PASI and moderate correlation with DLQI.
CI  - (c) 2021. The Author(s).
FAU - Leonardi, Craig
AU  - Leonardi C
AD  - Central Dermatology, St. Louis, MO, USA. Craig.Leonardi@centralderm.com.
FAU - See, Kyoungah
AU  - See K
AD  - Eli Lilly and Company, Indianapolis, IN, USA.
FAU - Gallo, Gaia
AU  - Gallo G
AD  - Eli Lilly and Company, Indianapolis, IN, USA.
FAU - McKean-Matthews, Missy
AU  - McKean-Matthews M
AD  - Eli Lilly and Company, Indianapolis, IN, USA.
FAU - Zhang, Ying
AU  - Zhang Y
AD  - Eli Lilly and Company, Indianapolis, IN, USA.
FAU - Goldblum, Orin
AU  - Goldblum O
AD  - Eli Lilly and Company, Indianapolis, IN, USA.
FAU - Mallbris, Lotus
AU  - Mallbris L
AD  - Eli Lilly and Company, Indianapolis, IN, USA.
FAU - Burge, Russel
AU  - Burge R
AD  - Eli Lilly and Company, Indianapolis, IN, USA.
AD  - University of Cincinnati, Cincinnati, OH, USA.
LA  - eng
PT  - Journal Article
DEP - 20210528
PL  - Switzerland
TA  - Dermatol Ther (Heidelb)
JT  - Dermatology and therapy
JID - 101590450
PMC - PMC8322262
OTO - NOTNLM
OT  - OPAT
OT  - PASI
OT  - Psoriasis
EDAT- 2021/05/29 06:00
MHDA- 2021/05/29 06:01
PMCR- 2021/05/28
CRDT- 2021/05/28 12:22
PHST- 2021/02/10 00:00 [received]
PHST- 2021/04/28 00:00 [accepted]
PHST- 2021/05/29 06:00 [pubmed]
PHST- 2021/05/29 06:01 [medline]
PHST- 2021/05/28 12:22 [entrez]
PHST- 2021/05/28 00:00 [pmc-release]
AID - 10.1007/s13555-021-00544-6 [pii]
AID - 544 [pii]
AID - 10.1007/s13555-021-00544-6 [doi]
PST - ppublish
SO  - Dermatol Ther (Heidelb). 2021 Aug;11(4):1249-1263. doi: 
      10.1007/s13555-021-00544-6. Epub 2021 May 28.